Marilyn Tavenner, president and CEO of America’s Health Insurance Plans, believes that while the tone of this year’s presidential election race has been interesting, the discussion among the candidates regarding issues of healthcare and coverage have generally been the same as elections in years past.
Marilyn Tavenner, president and CEO of America’s Health Insurance Plans, believes that while the tone of this year’s presidential election race has been interesting, the discussion among the candidates regarding issues of healthcare and coverage have generally been the same as elections in years past.
Transcript (slightly modified):
How much does a presidential election weigh on the minds of AHIP’s members? And is this election any different?
Well I think every time there’s an election, members are looking to see what is going to be the healthcare strategy of the presidential candidate. In this case, I think that we understand if you’re talking about Secretary Clinton, she’s been pretty clear about continuing to grow the ACA, making some improvements in the ACA, dealing with delivery system reform. Likewise, for Donald Trump, there’s been less detail but certainly there’s a Republican house we work closely with and they are in the process of putting together principles around healthcare strategy and many of those we endure such as delivery system reform and continuing coverage and quality improvements.
So probably not a lot different than — while the tone of this election’s certainly been more interesting, probably the issues are the same.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More